Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1.
Bratisl Lek Listy
; 122(8): 582-589, 2021.
Article
de En
| MEDLINE
| ID: mdl-34282625
ABSTRACT
OBJECTIVES:
Low molecular weight heparin (LMWH) may provide beneficial effects on outcomes of COVID-19. We aimed to examine the impact of LMWH treatment on clinical outcomes (duration of hospitalization, admission to intensive care unit, the requirement for mechanical ventilation, and death) of COVID-19 patients with normal D-dimer levels at admission.BACKGROUND:
Coronavirus disease-2019 (COVID-19) predisposes patients to arterial and venous thrombosis.METHODS:
In this retrospective, multicentre and observational study we analysed the data of 308 confirmed COVID-19 patients with normal D-dimer levels at initial admission. After propensity score matching (PSM) patients were grouped; Group 1; patients who received LMWH with D-dimer ≤0.5 mg/L, Group 2; patients who received LMWH after D-dimer levels exceeded 0.5 mg/L, and Group 3; patients who did not receive LMWH.RESULTS:
After PSM, each group comprised 40 patients. The patients in Group1 had the best clinical outcomes compared to the other groups. Group 3 had the worst clinical outcomes (p<0.005). The benefit of LMWH increased with early prophylactic therapy especially when started while the D-dimer levels were ≤0.5 mg/L.CONCLUSION:
Our results strongly suggest that proactive LMWH therapy improves clinical outcomes in hospitalized COVID-19 patients even with normal D-dimer levels (≤ 0.5 mg/L) (Tab. 3, Fig. 2, Ref. 34).Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Héparine bas poids moléculaire
/
COVID-19
Type d'étude:
Observational_studies
Limites:
Humans
Langue:
En
Journal:
Bratisl Lek Listy
Année:
2021
Type de document:
Article